Pages that link to "Q34417178"

The following pages link to Polymorphism of dextromethorphan oxidation in a French population (Q34417178):

Displaying 28 items.

• Genetic predisposition to drug-induced hepatotoxicity (Q28242387) (← links)
• Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers (Q28361024) (← links)
• Drug-induced liver diseases (Q33870235) (← links)
• Pharmacogenetics and psychopharmacotherapy (Q33962212) (← links)
• The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes (Q34346292) (← links)
• The effect of inhaled and oral dextromethorphan on citric acid induced cough in man (Q34347009) (← links)
• Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer (Q34358477) (← links)
• Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man. (Q34397246) (← links)
• Extensive oxidative metabolism of dextromethorphan in patients with almitrine neuropathy (Q34397478) (← links)
• Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients (Q34397748) (← links)
• The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. (Q34400605) (← links)
• Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone (Q34403471) (← links)
• Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. (Q38260323) (← links)
• Quantitation of levorphanol in human plasma at subnanogram per milliliter levels using capillary gas chromatography with electron-capture detection. (Q41679909) (← links)
• Genetic predisposition to drug hepatotoxicity: role in hepatitis caused by amineptine, a tricyclic antidepressant (Q42198417) (← links)
• Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism (Q42285032) (← links)
• Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients (Q42550142) (← links)
• A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine--application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition (Q44084843) (← links)
• A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study. (Q46010800) (← links)
• Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects (Q46825567) (← links)
• Induction of phencyclidine-like behavior in rats by dextrorphan but not dextromethorphan (Q52265584) (← links)
• Development of an ELISA to study the polymorphism of dextromethorphan oxidation in a french population (Q57997241) (← links)
• Phenotyping polymorphic drug metabolism in the French Caucasian population (Q67969799) (← links)
• Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations (Q68443393) (← links)
• Polymorphic O-demethylation of codeine (Q69925022) (← links)
• Low frequency of dextromethorphan O-demethylation deficiency in a Chinese population (Q71955655) (← links)
• Dextromethorphan O-demethylation polymorphism in Jordanians (Q72693312) (← links)
• Dextromethorphan metabolism in Jordanians: dissociation of dextromethorphan O-demethylation from debrisoquine 4-hydroxylation (Q73165258) (← links)